Abstract
The limited efficacy of current therapeutic approaches for a number of socially relevant human diseases has required the exploration of alternative and more effective therapeutic strategies. In the last three decades, nucleic acid based drugs (NABDs) have emerged as an attractive and novel alternative with great therapeutic potential. NABDs which include antisense oligonucleotides, decoys, aptamers, triple helix forming oligonucleotides, DNAzymes, Ribozymes and small interfering RNAs, have been shown to be able to efficiently counteract pathological gene expression in many different experimental systems. Despite their broad potential applicability, NABD use in the clinic is limited by the lack of optimal delivery systems. Due to their hydrophilic nature, NABDs cannot efficiently cross cellular membrane for which appropriate carriers are needed. Moreover, their instability in serum requires a proper protection to prevent a fast degradation which would invariably lead to the abrogation of any significant therapeutic effect. In this work we will review the strategies currently proposed to circumvent NABD delivery problems. Although the NABD delivery issue can and should be optimized to bring NABD closer to the clinic, the encouraging results displayed so far in experimental models fully justify further efforts both in terms of investments and scientific work. Keywords: Nucleic acid based drugs, therapeutic potential, delivery
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.